Veterinary composition for treating milk fever for milk-producing ruminants
By using the cabergoline composition to treat dairy cows during the dry milking period, the problem of postpartum hypocalcemia is solved, the maintenance of blood calcium concentration and the improvement of cow health is achieved, the food management is simplified, and the cost of disease treatment is reduced.
Patent Information
- Application Number
- CN202180011764.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-01-27
- Filing Date
- 2021-01-26
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2041-01-26
AI Technical Summary
The prior art is difficult to effectively prevent and treat postpartum hypocalcemia, resulting in metabolic disorders, insufficient energy and milk production disorders in dairy cows, affecting the health and milk production of cows.
Veterinary compositions containing cabergoline are used during the dry milking period, especially when dry, to treat and prevent postpartum hypocalcemia, maintain blood calcium concentrations at normal levels, and avoid symptoms of hypocalcemia.
Effectively prevent and treat postpartum hypocalcemia, maintain blood calcium concentration at 2.1 mmol/l or above, reduce the risk of hypocalcemia in milk-producing ruminants, improve the health and milk production capacity of dairy cows, simplify feed management, and reduce disease treatment cost.
Smart Images

Figure BDA0003771492290000051
Abstract
Description
[0001] The present invention relates to a veterinary composition and a method for treating postpartum hypocalcemia by administering the composition during the dry period. The veterinary composition and treatment method according to the present invention do not affect the milk production capacity and / or milk quality of ruminants during the subsequent lactation period.
[0002] In milk-producing ruminants, lactation usually lasts from 5 to 20 months. In dairy cows, 10 months is most common. After this lactation period, milking is stopped, usually abruptly, and the milk-producing ruminant should not produce milk until calving, when subsequent lactation begins. The period between cessation of milking and subsequent lactation, the latter usually at parturition (or calving for dairy cows), is called the "dry period" and is usually set at about 2 months (i.e. 56 to 70 days) in dairy cows.
[0003] Although the dry period is necessary to ensure optimal milk production during the subsequent lactation period, this dry period requires several dietary changes and shifts to adapt to the physiological needs of an animal that is no longer producing milk. These dietary changes cause many physiological disruptions and stresses in ruminants, such as disruption of the balance of digestive flora, reduction of stomach capacity and absorption, and changes in the size of the rumen and rumen mucosal villi. Finally, this dry period leads to a metabolism in ruminants that is very different from that observed during lactation. Therefore, during the resumption of lactation after parturition, ruminants are in a metabolically dysregulated state, resulting in an energy deficit, while the demand for milk production is once again at a maximum.
[0004] With the onset of lactation and ongoing milk production, dramatic adaptive changes occur in dairy cows due to the increased demand for nutrients to support milk synthesis. In addition to the increased energy and amino acid requirements for colostrum and subsequent milk synthesis, calcium requirements increase two- to three-fold relative to the cow's needs prior to calving. Shortly before calving, dairy cows deposit 8 g / d to 10 g / d of calcium into their fetuses, but when cows calve, they secrete 20 g / d to 30 g / d of calcium into colostrum and milk. Therefore, metabolic adaptations must occur to support the increased demand for calcium. If they do not occur quickly enough or are not large enough, the concentration of calcium in the blood decreases below a critical threshold, and clinical and subclinical hypocalcemia or milk fever can result.
[0005] Calcium is essential for skeletal tissue and smooth muscle, as well as for nerve function, including gastrointestinal motility and skeletal muscle strength. The lowest blood calcium concentration usually occurs within 12 to 24 hours after calving, and in healthy cows it usually returns to normal within 2 to 3 days after calving. Postpartum hypocalcemia (also known as milk fever) is caused by a temporary lack of blood calcium that usually occurs before and after delivery, and is one of the most common metabolic disorders in dairy cows. Early clinical or preclinical symptoms (stage 1: ruminants, and more specifically cattle, are still able to stand) can include excitability, nervousness, weight transfer, and dragging of the hind feet. Postpartum hypocalcemia is a common cause of poor labor / dystocia, stillbirth, and apparent sudden death in milk-producing ruminants and especially dairy cows. Clinical hypocalcemia is the most recognized dairy cow disease by dairy farmers, with an incidence of about 5%, sometimes up to 20%. The incidence increases with increasing milk production and continuous lactation.
[0006] The concentration of calcium in the blood is tightly regulated by controlling the absorption of dietary calcium and the release or uptake of calcium from the bones. Two hormones, parathyroid hormone (known as PTH) and 1,25-dihydroxyvitamin D3, control these processes. As the calcium concentration in the blood decreases, PTH is secreted and acts to reduce calcium excretion in the urine. This change allows only small adjustments in the concentration of blood calcium. If larger amounts of calcium are needed, such as with the onset and maintenance of lactation, PTH acts on the bones and calcium is reabsorbed and released into the blood. In addition, PTH acts on the kidneys and causes the conversion of vitamin D metabolites to 1,25-dihydroxyvitamin D3. 1,25-dihydroxyvitamin D3 can then regulate the absorption of calcium from the small intestine by active transport. In order for PTH to be secreted and effectively bind to its receptors, adequate magnesium and a slightly low alkaline blood pH (known as metabolic acidosis) are required, thus arguing that adequate amounts of magnesium should be provided before fresh foods and that these diets should be balanced to provide a negative cation-anion difference (DCAD) to prevent hypocalcemia. However, such specific diets may not be sufficient to avoid hypocalcemia.
[0007] As mentioned previously, some dairy cows may experience subclinical hypocalcemia, which does not show clinical signs but usually has low blood calcium concentrations within 24 hours after calving. One way to know if a dairy cow is experiencing subclinical hypocalcemia is to analyze the calcium concentration in the blood within the first 1 to 2 days after calving. Cows with blood calcium concentrations at or below 8.8 mg / dl (2.2 mmol / l) but who do not show clinical signs are considered to have subclinical hypocalcemia. It is estimated that the economic cost of subclinical hypocalcemia in a dairy herd is four times the cost of a clinical case, having a significant impact on the profitability of a dairy operation.
[0008] Postpartum hypocalcemia affects the health of postpartum cows, future milk production and reproductive performance. Studies have also shown that immune function is impaired in dairy cows with low blood calcium concentrations.
[0009] Prevention of postpartum hypocalcemia is often achieved by changing the fresh food front or anionic diet (close-up diet). These changes allow the physiological systems that mobilize calcium to be primed and prepared for the increased demand for calcium associated with the synthesis of colostrum and milk. However, such specific diets may be difficult to implement or may not be sufficient to avoid postpartum hypocalcemia.
[0010] There is a need for a method of preventing postpartum hypocalcemia in ruminants.
[0011] In veterinary medicine, compositions based on prolactin inhibitors such as (cabergoline, Ceva Santé Animale, France) can be administered as a therapeutic drug for lactation during pseudopregnancy in female dogs. They are also prescribed to stop milk production and lactation in ruminants. WO2010040765 in the name of the applicant describes the administration of anti-prolactin dopamine receptor agonist compounds (such as cabergoline) to ruminants during pregnancy in order to induce lactation dryness and promote mammary involution, especially by intramuscular administration. However, the administration of such cabergoline has never been used to treat or prevent postpartum hypocalcemia in ruminants.
[0012] The applicant has now surprisingly found that administration of a veterinary composition comprising cabergoline to a lactating ruminant during the dry period can treat, and more specifically prevent, postpartum hypocalcemia. Summary of the invention
[0013] The present invention relates to a veterinary composition comprising cabergoline for use in the treatment of postpartum hypocalcemia in a lactating ruminant, wherein the composition is administered to the lactating ruminant during the dry period and preferably at the time of dry period implementation (ie at dry-off).
[0014] According to the present invention, the composition is administered in a therapeutically effective amount during the dry period of a lactating ruminant and preferably at the dry-off of the lactating ruminant to treat hypocalcemia during the subsequent lactation period, particularly during and after farrowing.
[0015] The composition is administered to the ruminant once and / or several times, preferably once.
[0016] Administration of the veterinary composition according to the invention does not affect the milk production capacity and / or milk quality of the ruminants during the subsequent lactation period.
[0017] The present invention also relates to a kit for treating postpartum hypocalcemia in ruminants.
[0018] In one aspect, the present invention provides the use of cabergoline in the preparation of a veterinary composition for treating postpartum hypocalcemia in a ruminant, wherein the composition is administered to the ruminant during the dry period of the ruminant and preferably at the dry-off of the ruminant.
[0019] In another aspect, the present invention provides a method for treating postpartum hypocalcemia in a ruminant, wherein a veterinary composition comprising cabergoline is administered in a therapeutically effective amount during the dry period of the ruminant and preferably at the dry-off of the ruminant. DETAILED DESCRIPTION
[0020] The phrase "dry period" includes the time between the last milking of a lactation and the next milking of the next lactation, which usually begins at farrowing. The dry period usually lasts about 2 months in dairy cows, more specifically 45 to 70 days.
[0021] In the context of the present invention, the terms "last milking", "drying off" or "milking stop" are used interchangeably. They correspond to the time when the dry period is implemented.
[0022] The terms "postpartum hypocalcemia" and "milk fever" are used interchangeably and refer more specifically to clinical or subclinical hypocalcemia at parturition (and more specifically at calving in dairy cows), and as described above. Cows with blood calcium concentrations at or below 8.8 mg / dl (2.2 mmol / l) but who do not show clinical signs are considered to have subclinical hypocalcemia. Clinical signs of milk fever in dairy ruminants include, but are not limited to, muscle tremors of the head and extremities, recumbency, lethargy, cold extremities, or hypothermia.
[0023] As used herein, the terms "treatment", "treating" and "treat" are defined as the action of cabergoline or a composition comprising cabergoline on postpartum hypocalcemia to reduce or eliminate the risk of developing postpartum hypocalcemia, or to reduce or alleviate one or more symptoms, preferably all symptoms, of postpartum hypocalcemia. Symptoms include, but are not limited to, muscle tremors of the head and limbs, lying flat, lethargy, cold limbs or hypothermia. Therefore, it includes preventive treatment and / or curative treatment. "Treatment" as used herein includes: (a) reducing the risk of developing postpartum hypocalcemia or milk fever in milk-producing ruminants, (b) preventing the onset of a decrease in blood calcium levels, and / or (c) increasing blood calcium levels or maintaining blood calcium levels at normal levels, preferably reaching a blood calcium concentration greater than or equal to 2.1 mmol / l or preferably reaching 2.2 mmol / l in ruminants. Treatment, or more specifically prevention, of postpartum hypocalcemia includes treatment, or more specifically prevention, of muscle tremors of the head and limbs, recumbency, lethargy, cold extremities, or hypothermia due to hypocalcemia in a lactating ruminant.
[0024] The present invention relates to a veterinary composition comprising cabergoline for use in the treatment of milk fever, or more particularly for the prevention of milk fever, wherein the composition is administered to a ruminant during the dry period and preferably at dry-off.
[0025] The present invention also relates to a veterinary composition comprising cabergoline for use in the treatment of milk fever in milk-producing ruminants, said veterinary composition being administered in a single administration and / or in repeated administrations, preferably in a single administration, during the dry period and preferably at dry-off.
[0026] The administration of the composition according to the invention to a milk-producing ruminant more particularly allows the maintenance of a blood calcium concentration in the ruminant of a concentration higher than or equal to 2.1 mmol / l or preferably 2.2 mmol / l. More particularly, the administration does not require any particular diet, and more particularly does not require any dietary regimen aimed at maintaining a satisfactory blood calcium concentration in the ruminant (e.g. a diet with sufficient amounts of magnesium and balancing these diets to provide DCAD). The composition used according to the invention allows the maintenance of such a blood concentration during the dry period and more particularly at farrowing and after farrowing (i.e. at subsequent lactation).
[0027] The present invention also relates to a method for preventing and / or reducing postpartum hypocalcemia in a milk-producing ruminant, and a method for preventing milk fever in a milk-producing ruminant, the method comprising administering a veterinary composition comprising cabergoline to the ruminant during the dry period and preferably at dry-off according to an effective treatment regimen.
[0028] Preferably, the veterinary composition is administered to dairy cows.
[0029] More specifically, the veterinary composition for use according to the present invention is applied after the last milking. In a specific embodiment, the veterinary composition is preferably applied within the first 5 hours, the first 4 hours or the first 2 hours after the last milking, preferably within the first 30 minutes (such as 15-20 minutes) after the last milking.
[0030] The veterinary compositions and methods according to the invention are attractive to farmers because their use allows to maintain satisfactory blood calcium concentrations without having to worry about a specific blood calcium concentration increase regimen, leading to simplified herd management and savings in disease treatment costs when lactation is restored. Thus, the use of the compositions of the invention enables better management of the feeding program during the dry period.
[0031] Cabergoline, whose chemical name is N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-8g-ergoline-8-carboxamide, is an anti-prolactin agonist compound specific for D2 dopamine receptors. It is specifically described in patent US 4,526,892. Its chemical structure is as follows:
[0032]
[0033] Cabergoline is named and The active ingredient in human medicines sold under the name (for lactating bitches prone to false pregnancy) and name The essential active ingredient in the veterinary composition sold as veterinary medicine (for use in dairy cows to reduce the duration of udder involution during the dry period of dairy cows) and is administered as a single intramuscular injection. None of these cabergoline-based compositions have been administered to ruminants for the treatment of milk fever in milk-producing ruminants.
[0034] Effective amount or therapeutic dose may change according to the ruminant to be treated. Dosage (also referred to as treatment regimen) can be easily determined by system testing based on the following examples, and within the capabilities of those skilled in the art. According to a specific embodiment of the present invention, the effective therapeutic dose according to the present invention is between 1 μ g / kg and 50 μ g / kg, or between 5 μ g / kg to 11 μ g / kg, and more preferably about 6 μ g / kg to 9 μ g / kg.
[0035] More preferably, the amount of cabergoline administered is 0.25 mg to 7 mg, preferably 0.3 mg to 6 mg, and more particularly 1 mg to 6 mg per milk-producing ruminant.
[0036] More preferably, the amount of cabergoline administered is 2 mg to 7 mg, preferably 3 mg to 6 mg, and more particularly 5 mg to 6 mg per dairy cow.
[0037] According to the present invention, the term "ruminant" refers to a herbivorous mammal, such as, for example, bovines, ovines, caprines, camelids or bovids. The milk-producing ruminant of the present invention is preferably a pregnant ruminant. The composition according to the present invention is administered to a pregnant ruminant mammal that produces milk, preferably such as cows, sheep and goats, and more preferably cows.
[0038] Advantageously, the veterinary composition of the present invention can be administered in combination with standard therapeutic drugs for the treatment and / or prevention of intramammary inflammation and intramammary infection (e.g., mastitis) of ruminants. Examples of standard care or preventive compositions for mastitis are topical disinfectants of the udder, antibiotics such as penicillins of group M, cephalosporins, gentamicin or even enzymes such as lysozyme or muramase, and teat sealants.
[0039] As previously mentioned, postpartum hypocalcemia (also known as milk fever) is caused by a temporary lack of blood calcium that usually occurs around the time of parturition, more specifically when a cow calves. Milk fever usually occurs within the next 12 to 24 hours after parturition. According to a specific embodiment, postpartum hypocalcemia is treated within the next 12 to 24 hours after parturition.
[0040] According to a specific embodiment of the present invention, the treatment of postpartum hypocalcemia of the present invention comprises reducing or ameliorating the risk of developing postpartum hypocalcemia, particularly within the next 12 to 24 hours after delivery.
[0041] According to a particular embodiment of the invention, prevention and / or reduction of postpartum hypocalcemia in milk-producing ruminants refers to a treatment in which the ruminants present or achieve a satisfactory blood calcium concentration, which is generally higher than or equal to 2.1 mmol / L, preferably 2.2 mmol / L.
[0042] The veterinary compositions used according to the invention can be administered according to a variety of administration methods well known in the art and are suitable for treating each of these animals. They are preferably administered orally or parenterally. Even more preferably, they are administered by intramuscular or subcutaneous injection or by intramammary administration. According to a specific embodiment, they are administered intramammarily or preferably intramuscularly.
[0043] Thus, they may be in the form of oral, intramammary or injectable liquid solutions or suspensions, or in solid or semisolid form.
[0044] Depending on the formulation of the composition used, they may further include ingredients conventionally used in pharmacy for preparing liquid preparations for intramammary administration.
[0045] The injectable preparation is prepared by mixing a therapeutically effective amount of cabergoline as described above with a solvent, pH adjuster, buffer, suspending agent, solubilizer, stabilizer, tonicity agent and / or preservative, and by converting the mixture into subcutaneous or intramuscular injection according to a conventional method.
[0046] As solvents, there may be mentioned dimethyl sulfoxide (DMSO), oily solvents such as medium chain triglycerides, or mixtures of capric acid, caprylic acid and triglycerides, such as those sold under the name 812. As needed, the injectable preparation can be lyophilized according to conventional methods. Examples of suspending agents include methylcellulose, polysorbate 80, hydroxyethylcellulose, xanthan gum, sodium carboxymethylcellulose and polyethoxylated sorbitan monolaurate. Examples of solubilizers include polyoxyethylene hardened castor oil, polysorbate 80, nicotinamide, polyoxyethylene sorbitan monolaurate, polyethylene glycol and castor oil fatty acid ethyl ester. In addition, stabilizers include sodium sulfite, metal sodium sulfite and ether, and preservatives include methyl parahydroxybenzoate, ethyl parahydroxybenzoate, sorbic acid, benzyl alcohol, phenol, cresol and chlorocresol. An example of a tonicity agent is mannitol. During the preparation of injectable solutions or suspensions, it is necessary to ensure that they are isotonic with blood.
[0047] The present invention further relates to a kit for veterinary use for treating, more specifically reducing or alleviating, postpartum hypocalcemia in a milk-producing ruminant, wherein the kit comprises a veterinary composition comprising cabergoline as defined above, for treating postpartum hypocalcemia in a milk-producing ruminant. The kit according to the invention may comprise at least one compartment for optionally aseptic packaging, the packaging comprising an effective therapeutic amount of cabergoline as described above for administration to a ruminant. The kit comprises means enabling the composition to be administered by a selected route (e.g., intramammary or intramuscular route), as well as instructions relating to the mode of administration of the veterinary composition according to the invention.
[0048] All embodiments described above for the composition and the use of said composition also apply to the kit and method of the present invention.
[0049] The following are examples. These examples are illustrative rather than limiting.
[0050] Examples
[0051] Example 1: Effect of Cabergoline on Milk Fever in Dairy Cows
[0052] The cabergoline composition is a solution comprising cabergoline and dimethyl sulfoxide and medium chain triglycerides as excipients. It corresponds to the drug known as Velactis TM product (cabergoline 1.12 mg / mL).
[0053] The objective of this clinical study was to evaluate the long-term safety of a single intramuscular injection of a cabergoline composition as detailed above in dairy cows after the last milking, at dry-off, during the dry period and subsequent lactation. This was a multicenter, parallel, randomized, blinded experimental design evaluating the effects of the cabergoline composition as detailed above on milk heat at calving after the dry period relative to a negative control (placebo).
[0054] For the tested group, each cow was injected with 5.6 mg of the cabergoline composition (i.e., 5 ml / cow). The vehicle of the cabergoline composition of 5 ml / cow was injected into the control group (i.e., 0 mg / ml of cabergoline). Each animal was treated by intramuscular injection within 4 hours after the last milking at dry off.
[0055] The total number of cows included in the study was 255 (126 in the tested group and 129 in the placebo group). Both groups were comparable in terms of their baseline criteria at the time of inclusion.
[0056] Milk fever was assessed and recorded by the veterinarian at calving in both groups.
[0057] The incidence of milk fever in each group is given in Table 1.
[0058] Table 1: Milk production heat in each group
[0059] Milk fever detection Tested Groups (N=126) Placebo group (N=129) Total (N=255) no <![CDATA[99.18% 1 (121) 2 ]]> 89.52%(111) 94.31%(232) yes 0.82%(1) 10.48%(13) 5.69%(14) miss (4) (5) (9)
[0060] 1 Percentage of cows showing symptoms of milk fever
[0061] 2 The number of cows in brackets
[0062] Taking into account all the calving criteria (abortion, premature birth, calving mode, number and general health of calves, calving complications and length of pregnancy) and all the reproduction criteria (estrus synchronization, treatment of the first estrus occurrence, pregnancy diagnosis, interval between calving and first estrus and between calving and fertilization, ...) throughout the study, no relevant differences were observed between the tested group and the placebo group. In the same way, the results of the uterine and ovarian examinations after calving in the cows treated with the cabergoline composition were comparable to those obtained in the animals treated with the placebo, and the milk yield and somatic cell count (SCC) recorded during all lactations were similar between the two groups. The milk yield was even slightly higher in the tested group compared to the placebo group.
[0063] Milk fever at calving (10.5% of cows) was recorded most in the placebo group. The percentage of cows with milk fever at calving was significantly lower in the tested group compared to the placebo group (p<0.05). It was also associated with a relatively low risk of milk fever of about 92.2%, with CI95% = [41.2%; 99.0%] (calculated by statistical analysis).
[0064] In conclusion, the veterinary composition comprising cabergoline reduces the risk of developing milk fever in a very satisfactory and simple manner. It is also important to note that such treatment does not affect the milk production capacity and / or milk quality (such as SCC) of the ruminants during the subsequent lactation.
Claims
1. The use of cabergoline for the preparation of a veterinary composition for the treatment or prevention of postpartum hypocalcemia in a milk-producing ruminant, wherein the composition is administered to the milk-producing ruminant during the dry period, at the time of drying off, and wherein the composition is administered within the first 5 or first 4 hours after the last milking.
2. The use of cabergoline according to claim 1, for reducing or eliminating the risk of developing milk fever in milk-producing ruminants.
3. The use of cabergoline according to claim 1 or 2, wherein the composition is administered once and / or several times.
4. The use of cabergoline according to claim 1 or 2, wherein the composition is administered at a dose of 1 μg / kg to 50 μg / kg, or 5 μg / kg to 11 μg / kg.
5. The use of cabergoline according to claim 1 or 2, wherein the amount of cabergoline administered is 0.25 mg to 7 mg per milk-producing ruminant.
6. The use of cabergoline according to claim 1 or 2, wherein the amount of cabergoline administered is 2 mg to 7 mg per dairy cow.
7. The use of cabergoline according to claim 1 or 2, wherein the ruminant is a herbivorous mammal selected from bovines, ovines, caprines, camelids or cattle.
8. The use of cabergoline according to claim 1 or 2, wherein the ruminant is a milk-producing ruminant mammal.
9. The use of cabergoline according to claim 1 or 2, wherein the treatment reduces or eliminates the risk of developing postpartum hypocalcemia.
10. The use of cabergoline according to claim 1 or 2, wherein the composition is administered intramammarily or intramuscularly.
11. The use of cabergoline according to claim 1 or 2, wherein cabergoline is contained in a veterinary composition, and the veterinary composition is contained in a kit.
